Imatinib mesylate, a clinically approved tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia and gastrointestinal stromal tumors, is known to interact with transferrin and may be repurposed based on its newly predicted affinity for CHP1 [76,77]. This evidence concerns the gene TF and chronic myelogenous leukemia, BCR-ABL1 positive.